Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company^™, is pleased to announce an upcoming Nature webinar featuring Gloria Sheynkman, Ph.D., Associate Professor, University of Virginia, who will present new findings from her recent preprint on sequencing proteoform variation with Next-Gen Protein Sequencing^™ (NGPS^™). The live webinar will take place on May 15, 2025, at 8:00 a.m. PDT / 11:00 a.m. EDT.

Proteins are central to cellular function, yet traditional proteomics methods, including mass spectrometry and affinity-based approaches, face challenges in resolving proteoforms, the distinct molecular variation arising from alternative splicing, genetic mutations, and post-translational modifications.

Quantum-Si is pioneering the next generation of protein sequencing technologies, delivering single-amino acid resolution and enabling detection of endogenous proteins with high specificity.

In this context, Dr. Sheynkman's presentation, titled “Precision Proteomics: Next-Gen Protein Sequencing for Proteoform Detection and Characterization” highlights research from her team’s latest study on tropomyosin proteoforms. The work showcases the power of Quantum-Si’s Platinum^® family of Next-Gen Protein Sequencing instruments in capturing protein diversity at the single-molecule level.

The webinar is hosted by Nature Portfolio and offers attendees an opportunity to hear directly from Dr. Sheynkman about her lab’s innovative multiomic approaches to decoding the proteome.

Webinar Details:

Date: Thursday, May 15, 2025

Time: 8:00 a.m. PDT / 11:00 a.m. EDT

Registration and More Information: Nature Webinar Registration Page

To learn more about the study, read the original press release here:

University of Virginia Researchers Publish New Study on Tropomyosin Proteoforms Showcasing Quantum-Si’s Next-Gen Protein Sequencer Platinum

For more information on the webinar, visit: Quantum-Si

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company^™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum^® line of instruments enables Next-Gen Protein Sequencing^™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and any financial guidance for the full year 2025. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum^® protein sequencing instruments and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250512868704/en/